Published in Transpl Int on July 10, 2008
Regulatory immune cells in transplantation. Nat Rev Immunol (2012) 1.82
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther (2012) 1.14
Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg (2010) 1.08
Pathogenic and protective role of macrophages in kidney disease. Am J Physiol Renal Physiol (2013) 0.97
Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res (2012) 0.92
Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol (2012) 0.91
Tolerogenic therapies in transplantation. Front Immunol (2012) 0.88
Tolerance in clinical transplantation: progress, challenge or just a dream? Langenbecks Arch Surg (2011) 0.88
Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort. Mediators Inflamm (2015) 0.87
In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. Mol Ther Methods Clin Dev (2014) 0.84
Regulatory myeloid cells in transplantation. Transplantation (2014) 0.83
Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation. Front Immunol (2016) 0.77
Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms. Front Immunol (2016) 0.76
The long and winding road towards induction of allograft tolerance in the clinic. Transpl Int (2008) 0.75
Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation. Front Immunol (2017) 0.75
Tolerance--is it worth it? Cold Spring Harb Perspect Med (2014) 0.75
The exciting "bench to bedside" journey of cell therapies for acute kidney injury and renal transplantation. J Nephrol (2017) 0.75
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet (2007) 2.75
Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res (2007) 2.71
Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int (2012) 2.55
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med (2002) 2.20
Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2013) 2.10
Cutting edge: CCR7+ and CCR7- memory T cells do not differ in immediate effector cell function. J Immunol (2002) 1.98
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84
Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int (2010) 1.70
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant (2005) 1.50
No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant (2004) 1.43
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Images in clinical medicine. Radiographic appearance of lanthanum. N Engl J Med (2006) 1.39
Selective decontamination of the digestive tract: impact on cytokine release and mucosal damage after hemorrhagic shock. Crit Care Med (2002) 1.39
Present status and perspectives of cell-based therapies for liver diseases. J Hepatol (2006) 1.33
Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-α-induced shock. Mol Med (2012) 1.31
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer (2011) 1.30
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology (2005) 1.26
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a large German case-control sample. Int J Cancer (2009) 1.25
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17
Programmed necrosis in acute kidney injury. Nephrol Dial Transplant (2012) 1.17
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther (2012) 1.14
Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. BMC Gastroenterol (2012) 1.13
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int (2005) 1.11
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol (2008) 1.10
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer (2008) 1.10
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis (2009) 1.08
Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int (2011) 1.07
Tracking of human cells in mice. Histochem Cell Biol (2008) 1.06
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Duration of donor brain death and its influence on kidney graft function. Am J Transplant (2002) 1.04
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res (2004) 1.02
Mesenchymal stem cells can affect solid organ allograft survival. Transplantation (2009) 1.01
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res (2004) 1.01
The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol (2013) 1.00
The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors. Curr Cancer Drug Targets (2011) 1.00
Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany. BMC Gastroenterol (2006) 1.00
Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol (2005) 0.99
Procedures for ethical review for clinical trials within the EU. BMJ (2009) 0.99
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). J Transl Med (2011) 0.97
Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis (2005) 0.97
Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl (2009) 0.97
Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem (2004) 0.95
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta (2010) 0.95
Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology (2009) 0.94
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells. Int J Oncol (2011) 0.94
No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells (2006) 0.94
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer (2008) 0.94
Programmable cells of monocytic origin (PCMO): a source of peripheral blood stem cells that generate collagen type II-producing chondrocytes. J Orthop Res (2008) 0.93
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther (2008) 0.93
Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol (2011) 0.93
Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res (2012) 0.92
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther (2007) 0.92
Embryonic stem cells share immune-privileged features relevant for tolerance induction. J Mol Med (Berl) (2002) 0.92
Ectopic expression of CCL19 impairs alloimmune response in mice. Immunology (2004) 0.92
CCR7 signaling inhibits T cell proliferation. J Immunol (2007) 0.92
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int (2014) 0.92
Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer. Int J Cancer (2007) 0.91
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res (2012) 0.90
CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking. J Am Soc Nephrol (2006) 0.90
Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. Mol Cancer Res (2009) 0.90
Caspase 3 inhibition improves survival and reduces early graft injury after ischemia and reperfusion in rat liver transplantation. Transplantation (2004) 0.90
Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem (2005) 0.89